



## **GVK BIO and US FDA Announce Drug Repositioning Collaboration – License to GVK BIO SAR Database GOSTAR**

**Hyderabad, India – June 19th, 2013** – GVK Biosciences (GVK BIO) today announced that it has licensed its popular SAR, PK and Toxicity Database (GOSTAR) to the US Food and Drug Administration (USFDA). The Material Transfer Agreement forms the basis of collaboration in Drug Repositioning, wherein the initial focus will be to identify alternative therapeutic indications of marketed compounds for neglected and orphan diseases.

GVK BIO developed a proprietary 'Drug Repurposing Platform' with eight different approaches to address the drug repurposing challenge. The platform will use data from GVKBIO proprietary databases such as SAR databases (GOSTAR), Biomarker database (GOBIOM) and other public databases.

GOSTAR, a manually curated database, has been developed over the span of a decade by a team comprising of more than 200 scientists. The database and application is being used globally by pharmaceutical and biotechnology companies as well as academia and has been cited in numerous publications. GOSTAR contains over 6.5 million compounds manually curated through the manual screening of over 2.5 million patents and 400,000 journals and it also contains more than 18 million quantitative SAR points.

GOSTAR is the final outcome after the integration of over fifteen individual databases, which includes the complete chemical space for ten of the popular biological targets. In addition to this, the MedChem Databases include all published and patented inhibitors against biological targets that exceed 6,500 in number. GOSTAR also has four Toxicity and Natural Products databases.

Sreeni Devidas, Vice President, Business Development said "*The collaboration with the USFDA is a validation of the utility of GOSTAR in multiple applications. Specifically the ROI generated by the use in Drug Repositioning is unparalleled. GVK BIO will work with the USFDA to further enhance the Repositioning and Repurposing workflow and make it available to the entire research community*".

Manni Kantipudi, CEO, GVK Biosciences said "*Drug Repositioning is gaining traction in the industry and in academia, and is becoming a mandatory component of the Drug Development Process. The GOSTAR product will prove valuable in allowing researchers to use multiple Repositioning and Repurposing approaches and address multiple targets*".

*in parallel. We look forward to continue working and collaborating with the FDA with a view to further enhancing the utility of the product.”*

### **About GVK BIO**

GVK Biosciences (GVK BIO) is Asia’s leading discovery, research and development organization providing a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO has now been working with multiple clients offering Drug Repositioning and Repurposing as a target. Workflows have also been built into the GOSTAR database to facilitate this rapidly growing area of research. Please visit us at [www.gvkbio.com](http://www.gvkbio.com) to know more.

### **About GVK**

GVK is a leading Indian conglomerate with presence across energy, resources, airports, transportation, hospitality and life sciences sectors. GVK set up India’s first independent power plant and has around 6000 MW projects under generation and development. It is the first company in India to develop six-lane road project under PPP model and has around 3000 lane km expressway projects under operations and development. As one of India’s largest private sector airport operators, GVK handles 44 mppa through India’s first brownfield airport under PPP model – Chhatrapati Shivaji International Airport, Mumbai and Bengaluru International Airport, Bangalore and will develop two airports in Indonesia. Having already invested over USD 3.3 billion, GVK has projects worth over another USD 6.6 billion in the pipeline, in India. It has acquired Australian Coal Mines in Queensland with 8 bt reserves for USD 1.26 billion and envisages an investment of USD 10 billion to for setting up mines, 500 km rail project and 60 mtpa port project which will form one of the world’s largest integrated coal mining operations.

For any further information, please contact:

<p><b>Sreeni Devidas</b> Vice President – Business Development GVK Biosciences Private Limited Columbia, MD 21045 T (443)-838-6260 E <a href="mailto:sreeni.devidas@gvkbio.com">sreeni.devidas@gvkbio.com</a> W <a href="http://www.gvkbio.com">www.gvkbio.com</a></p>	<p><b>Sushant Datta</b> DGM – Corporate Brand &amp; Communications GVK Biosciences Private Limited Nacharam, Hyderabad T 0091 40 66929999 E <a href="mailto:sushant.datta@gvkbio.com">sushant.datta@gvkbio.com</a> W <a href="http://www.gvkbio.com">www.gvkbio.com</a></p>
--	---